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Abstract 
 
The prosperous polyphenol resveratrol have shown healthy benefits and anti-cancer 
properties, but the effect of resveratrol on cell morphology is less studied. The anti-
suppressant rapamycin, targets mTOR (the mammalian target of rapamycin), which 
exist in two complexes in mammals (mTORC1 and -2), and have in recent studies 
controversially showed that both complexes are inhibited by rapamycin. Resveratrol 
seems to somehow to interact with the mTOR and PI3K-Akt and the treatment of 
rapamycin plus resveratrol is therefore interesting to study. The PI3K-Akt pathway is 
known as an important role of cell growth and migration by regulating F-actin 
(filamentous actin) assembly. The morphological changes to the human epithelial 
colon cancer cell line, DLD-1, treated with 60 µM resveratrol and 0.5 µM rapamycin 
was scanned with atomic force microscopy (AFM). The cells were incubated for 48 
and 72 hours, fixated and scanned in air, and hereafter size and height were 
measured. The results show that resveratrol enhance the area about 8 times, when 
compared to untreated and rapamycin-treated cells. Resveratrol plus rapamycin 
increase the area but less than the sole resveratrol treatment. Incubation of 
resveratrol and/or rapamycin decreases the height the cells. 
Keywords  
Resveratrol, rapamycin, mTOR, AFM, Cell morphology, Akt. 
Readers Guide 
The report is build up with a theory section focusing on the biological processes on 
less on the physical aspects of the mechanism behind the AFM. The experiments used 
are briefly described so are the various techniques used in this project. Depending on 
the readers own experience these sections can be read according to his or hers 
level. Even Though we have tried to only describe the processes and substrates 
involved in our experiment, others have to mention because of the complexity of the 
pathways involved. Common used abbreviations are put in the bottom of this page.  
3 
 
 
Acknowledgement 
Above all, we would like to thank our supervisor; Associate Professor Ole Vang, 
Roskilde University, for his inspiration and guidance.  
Next we will like to thank Ph.D. Stud Peter Kristian Kristoffersen, for his many hours of 
technical support, his guidance and insight.  Without his help this project would not 
have been possible. 
We would also like to thank the lab-staff of Professor Ole Vang and Professor Birgitte 
Munch Petersen, for help when needed. We also like to thank the people of Cismi, for 
kindly providing us with the equipment of the Atomic Force Microscopy (AFM) and 
their software. 
Abbreviations  
4E-BP1, the eukaryotic initiation factor 4E (eIF4E) binding protein 1; AFM, atomic force 
microscopy; Arp2/3 complex, actin-related proteins 2/ 3; BPAEC, Bovine pulmonary 
artery endothelial cells; FAT domain, FRAP, ATM, TRAP;  F-actin, filamentous-actin; 
FKBP12, FK506 Binding Protein; FRB, FKBP12 rapamycin-binding; G-actin, globular 
actin; GβL, G-protein β-subunit like protein; Girdin/APE, girders of actin filaments/Akt 
phosphorylation Enhancer; mSIN1, Mammalian Stress-activated protein kinase 
Interacting protein 1 mTOR, mammalian target of rapamycin; mTORC1/2, mammalian 
TOR complex 1/ 2; NF-κB, nuclear factor-kappa B;  PAK, p21-activated kinase 
complex; PDK, protein dependent kinase; PDK1/ 2, phosphoinositide-dependent 
kinase 1/ 2; PH domain, pleckstrin homology domain; PI3K, Phosphoinositide 3-kinase; 
PIP2, phosphatidylinositol (4,5)-biphosphate; PIP3 (phosphatidylinositol (3,4,5)-
triphosphate; PIX, PAK-interacting protein; PKB, protein kinase B; PKC, protein kinase 
C;  PRAS40, proline-rich Akt substrate of 40 kilodaltons; PTEN, Phosphatase and Tensin 
homolog; Raptor, regulatory associated protein of mTOR; Rheb, Ras homolog 
enriched in brain; Rictor, rapamycin-insensitive companion of mTOR; S6K1, p70-S6 
Kinase 1; TSC1/ 2, tuberous sclerosis complex1/ 2; 
4 
 
 
Table of Contents 
Abstract........................................................................................................................ 2 
Keywords ............................................................................................................. 2 
Readers Guide.................................................................................................... 2 
Acknowledgement............................................................................................ 3 
Abbreviations...................................................................................................... 3 
Table of Contents ............................................................................................... 4 
Problem formulation ................................................................................................ 6 
1. Introduction ........................................................................................................... 6 
2. Theory ...................................................................................................................... 7 
2.1 Resveratrol..................................................................................................... 7 
2.2 Rapamycin.................................................................................................. 10 
2.4  mTOR........................................................................................................... 11 
Upstream of mTOR..........................................................................................................12 
2.4.1 mTORC1 .....................................................................................................................13 
2.4.1.1 Raptor ..................................................................................................................14 
2.4.1.2 PRAS40 .................................................................................................................14 
mLST8/GβL .......................................................................................................................14 
2.4.2 Downstream of mTORC1.........................................................................................15 
2.4.3 mTORC2 .....................................................................................................................16 
2.4.3.1 Rictor ....................................................................................................................16 
2.4.3.2 SIN1/MIP1.............................................................................................................17 
2.4.3.3 PPR5L/ Protor .......................................................................................................18 
2.3 PI3K/Akt pathway....................................................................................... 19 
Girdin/APE ...........................................................................................................................21 
5 
 
2.5 Cell morphology......................................................................................... 23 
2.5.1 Actin filaments...........................................................................................................23 
2.5.2 Rho family of small GTPases ....................................................................................24 
2.5.2 Regulation of cytoskeleton .....................................................................................25 
2.6 AFM............................................................................................................... 27 
3. Materials and Methods .................................................................................... 31 
3.1 Culture Medium, chemicals etc. ............................................................. 31 
3.2 Instruments and Software ......................................................................... 31 
3.3 Cell line and cultivation ............................................................................ 31 
3.4 AFM Sample Preparation.......................................................................... 32 
3.5 Resveratrol and rapamycin treatment................................................... 32 
3.6 Fixation with glutaraldehyde and osmium tetroxide............................ 34 
3.7 AFM Scanning............................................................................................. 37 
4 Results..................................................................................................................... 39 
4.1 phase contrast images.............................................................................. 39 
4.2 Area.............................................................................................................. 40 
4.3 Height........................................................................................................... 44 
4.3 AFM images ................................................................................................ 48 
4. Discussion.......................................................................................................... 51 
6. Conclusion and Perspective .............................................................................. 53 
7. Sources................................................................................................................... 54 
 
6 
 
 
Problem formulation 
How will the effect of resveratrol influence mTOR pathway of the human colon 
cancer cell line DLD-1, and what will we observe when combined with rapamycin 
and scanned in atomic force microscopy? 
1. Introduction 
Since the human genome has been available, novel therapeutic strategies has 
changed from a protein-centric view towards a more pathway-centric view. We will 
in this report try to add new knowledge to this global project. We have used a human 
colon cell line (DLD-1) and treated it with resveratrol and rapamycin. The 
morphological changes were observed by AFM (atomic force microscopy,) and the 
results are discussed in respects to new knowledge regarding the feasible pathways 
involved. Since the first microscope was used to study the scrapings of a tooth or 
some dirty rainwater, a new world of microorganisms and even smaller parts have 
emerged in front of us. We were given the opportunity to use a relative new 
microscope, in the biological regiment, to study changes on a cellular level.  
 
Resveratrol is found in a range of consumer products including grapes, red wine and 
peanuts, and it is believed to give benefits to the health. One of the proven effects of 
resveratrol is an anti-proliferative effect on cancer cells [Aggarwal et al., 2004; Aziz et 
al., 2003]. Resveratrol have shown to induce morphology changes on for example 
bovine pulmonary artery endothelial cells (BPAEC) [Bruder et al., 2001], human 
leukaemia cell line HL-60 and the human Hepatocellular carcinoma cell line HepG2 
[Stervbo et al., 2006b]. These changes in cell size have been observed on several 
occasions in our institute. 
 
Rapamycin was initially used to suppress the immune system in patients with organ 
transplantations. Later rapamycin has been used as a cytostatic, showing to arrest 
cell growth in tumours and to block the mTOR pathway. Thus, we hypothesized that 
the morphological changes induced by resveratrol could be decreased or inhibited 
by adding rapamycin to the assay.  
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AFM is a relatively new tool for studying biological samples. We had to fixate the cells, 
which is necessary for scanning biological samples in air. The analysis of the cell area 
and heights, plus two and three dimensional pictures were obtained.  These, to our 
knowledge, unique AFM pictures of resveratrol plus rapamycin treated cells, 
combined with new knowledge, shed light on some of the questions regarding the 
pathways and some of the many roles of resveratrol.  
 
This project will not discuss the AFM technique in details and the role of resveratrol 
and rapamycin as an anti-carcinogenic drug. The scanning done by the AFM gave 
many options regarding analysis and literature search, we have chosen to focus on 
the pathway from the drugs; resveratrol and rapamycin, through mTOR and PI3K/Akt, 
to the F-actin assembly. In the analysis of the scanned cells we chose to focus on the 
actin structures in the cells. The peaks of the cells, observed in the resveratrol- and 
resveratrol plus rapamycin-treated cells, are an interesting field to, but will not be 
discussed in this report. 
 2. Theory 
2.1 Resveratrol   
Resveratrol, first isolated in 1940 from the roots of white hellebore (Veratrum 
grandiflorum)  as an antifungal/antibacterial agent, showed later anti-inflammatory 
and anti-carcinogenic properties plus indicated a cardioprotective role, associated 
with the “French paradox” [Renaud and de Lorgeril, 1992]. 
The antioxidant resveratrol (3,5,4´-trihydroxystilbene) is a polyphenolic natural product 
synthesized by a range of plant species, including grapes, nuts, pines and berries. The 
concentration found in peanuts and berries are normally low. It is especially in the skin 
and seeds of red grapes that the concentration of resveratrol is high, but the 
bioavailability are negligible as no resveratrol can be found in plasma after ingestion 
[reviewed in Bertelli, 2007]. Red wine seems to be the major source in the western 
world. The concentration varies from grape species, product year, climate and other 
factors [Stervbo et al., 2006a].The concentration of resveratrol seems to be higher in 
organic wines, compared to conventional produced wines, which might be due to 
the elevated risk of attack by fungicides and bacteria, making the grapes produce 
more antifungal/antibacterial agents [Dani et al., 2007]. The Japanese knotweed has 
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a particular high concentration and is now used to produce commercial resveratrol 
supplements.   
 
Figure 1 Resveratrol in its trans-form (3,5,4´-trihydroxystilbene) - a stilbene (two phenols, which are 
joined by a 3 carbon chain, containing a double bond in the middle)  with 3 hydroxy groups. 
[www.wikipedia.org]. 
Resveratrol has shown to interfere with the pathways: PI3K/Akt, MAPK (Mitogen-
activated protein MAP kinases) and NF-κB (nuclear factor-kappa B) and to induce 
necrosis and/or apoptosis. 
In the PI3K/Akt pathway, resveratrol was found to inhibit cell transformation by 
blocking the EGF-induced (epidermal growth factors) activation PI3K/Akt  in 
epidermal cells of mice and down regulate EGF in human endometrial 
adenocarcinoma cells (the Ishikawa cell line, derived from a 39 year-old Asian 
woman). In human breast cancer cells, resveratrol interfered with an estrogen 
receptor-associated PI3K pathway, thereby blocking PI3K activation. Resveratrol has 
also shown indications of interfering with the receptor tyrosine kinase pathway. 
In the MAPK pathway, resveratrol inhibited the signalling in cervival carcinoma cells 
and has shown to require p53 activation and subsequent apoptosis. Resveratrol has 
shown to phosphorylate p53 in an epidermal mouse cancer cell line and in thyroid 
carcinoma cell lines. Different concentrations of resveratrol seem to influence the 
MAPK pathway differently in human neuroblastoma cells. 
Resveratrol has furthermore shown to suppress angiotensin and LDL (low density 
lipids), inhibit proliferation and to induce apoptosis in smooth muscle cells. 
Resveratrol-induced angiotensin II-suppression in smooth muscle cells (in rats) has 
shown to activate PI3K/Akt, ERK1/2 and S6K1 [reviewed in Fulda and Debatin, 2006]. 
The cardio protective effects of resveratrol has recently been linked the activation of 
Akt, which generates a survival signal through Thioredoxin [Das et al., 2008]. 
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Resveratrol has also shown to inhibit glucose metabolism in epithelial ovarian cancer 
cells (human cell lines). Cancer cells, with elevated glycolysis, seem to be sensitive to 
glycolysis-inhibition, and many tumours often rely on glycolysis rather than oxidative 
phosphorylation for ATP production. This is called the Warburg effect [Warburg, 1956]. 
The autophagocytosis mimics that of caloric restriction. This might be due to Akt 
inhibition, which is often elevated in ovarian cancer. Studies have shown that 
resveratrol inhibits Akt and mTOR signalling in a time and dose-dependent manner in 
a human ovarian cancer cell line, A2780.  However normal epithelial cells were not 
affected by resveratrol [Kueck et al., 2007].  
Studies of resveratrol and morphological changes in endothelial cells have shown 
that resveratrol changes the cell shape [Bruder et al., 2001]. Stervbo et al. showed 
that resveratrol-treated HL-60 (human promyelocytic leukemia) and HepG2 cells 
(human hepatocellular carcinoma cell), increased in nuclear size and granularity. 
Increased cell granularity has been linked to apoptosis. The increased nuclear size is 
less studied, but the change in the nuclear membrane morphology, was proposed to 
be linked with the cell cycle arrest in the S-phase [Stervbo et al., 2006b].  
Other Studies of the effects of resveratrol on cell morphology in have indicated that 
resveratrol interfere with the signalling cascades involving in F-actin (filamentous-
actin) assembly and that PKC (protein kinase C) signalling is a target of resveratrol 
[Slater et al., 2003] (both described in the cell morphology section). It has been shown 
that resveratrol incorporates into the cell membrane [Garcia-Garcia et al., 1999]. The 
results seem to support the contention that the beneficial effects of resveratrol may 
be mediated by an impact on membrane-associated PKC activity and the 
associated signalling networks. The effect of resveratrol on cell morphology, 
regarding its inhibitory effect on PKC isozymes, seems to explain some of resveratrol´s 
beneficial effects on cellular and cardiovascular functions. However resveratrol 
seems to bind to only some isozymes and especially when they are membrane 
bound [reviewed in Slater et al., 2003]. For example binds resveratrol to PKCα with 
higher affinity than other PKC´s [Garcia-Garcia et al., 1999] and to class II PI3K 
(described in the PI3K-Akt section) [Srivastava et al., 2005]. 
Another study with the cell line HepG2 showed that resveratrol furthermore reduces 
the dNTP pool (deoxyribonucleoside triphosphates) [Horvath et al., 2005].  
Studies in prolonged lifespan due to caloric restriction, shows similarities with 
resveratrol treatment, which mimics the Sir2 dependent lifespan extension during 
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caloric restriction. SIRT1 is a mammalian homolog to Sir2, which is activated by 
resveratrol. SIRT1 is known to regulate longevity, apoptosis, DNA repair and to 
facilitate changes in nutritional levels by NAD+ levels [Lagouge et al., 2006].  
2.2 Rapamycin 
Rapamycin was found in the soil of the Easter Island Rapa Nui in 1965. Rapamycin is a 
macrocylic lactone product of the soil bacteria Streptomyces hygroscopius [Paghdal 
and Schwartz, 2007]. Macrocylic lactones are natural antibiotics belonging to a class 
called polyketides. Polyketides are secondary metabolites not directly involved in the 
normal growth, development and reproduction as primary metabolites, but involved 
in for example, defend and communication. Rapamycin was isolated in 1975 and first 
identified as an antifungal antibiotic [Vezina et al. 1975].  
 
Figure 2 Structure of Rapamycin [Paghdal and Schwartz, 2007] 
In 1999 rapamycin was approved by FDA (the Food and Drug Administration) as an 
immunosuppressive drug under the name Rapamune ® as a prophylaxis of organ 
rejection. In 2000 it was approved in Europe.  Rapamycin is also known as sirolimus. 
Rapamycin was initially used to suppress the immune system in patients with organ 
transplantations. Later rapamycin has been used as a cytostatic, showing to arrest 
cell growth in tumours either by inducing apoptosis or arresting cells in the G1 phase, 
leading to a suppression of T-lymphocyte activation and proliferation. Rapamycin has 
also been used in studies and case reports for patients with tuberous sclerosis, psoriasis 
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Kaposi´s sarcoma, which is a AIDS defining illness caused by a human herpesvirus 
[Paghdal and Schwartz, 2007]. 
Rapamycin has shown to be a difficult clinical anti-cancer agent because of its poor 
water solubility and its poor stability in solution. Two analogues, CCL-779 and RAD001 
(everolimus) with improved clinical use has been synthesized and have entered 
clinical trials. 
Rapamycin binds to the intracellular receptor FKBP12 (FK506 Binding Protein) forming 
an inhibitory complex which interacts with the protein kinase mTOR (mammalian 
target of rapamycin) [Sarbassov et al. 2005]. FKBP12 is an immunophilin that binds to 
immunosuppresive drugs. FK506 or tacrolimus are other examples of an 
immunosuppresive drugs derived from soil bacteria, which binds to FKBP12 [Kino et al., 
1987]. Rapamycin binds to a region in the C terminus or TOR called FRB (FKBP12 
rapamycin-binding) causing inhibition of TOR activity by binding to the mTORC1 
(mTOR complex 1) [Hay and Sonenberg, 2004]. By its inhibition of mTOR, rapamycin 
has also shown to decrease VEGF concentration [Paghdal and Schwartz, 2007]. 
mTOR however, exists in two complexes, and “the classic theory” says that only 
TORC1 binds to the FKBP12-rapamycin complex [Sarbassov et al. 2005]. However 
recent studies have shown that mTORC2 is also affected by rapamycin [Sarbassov et 
al., 2006] (explained in the mTOR section). 
2.4  mTOR 
mTOR (mammalian target of rapamycin) is essential for growth and proliferation. If 
the TOR gene is disrupted the result is lethal. In human beings, a dysfunctional mTOR 
pathway are seen many cancer forms and in diseases. mTOR was identified and 
cloned in 1994 shortly after the discovery of TOR1 and TOR2 in s. Cerevisiae (yeast) 
during a screen for resistance to rapamycin. Where s. Cerevisiae has two different 
TOR proteins, the human analogue is a single protein. The mammalian protein 
however, exists in two distinct complexes mTORC1 and mTORC2 [Sarbassov et al., 
2005a] both which are essential [Thedieck et al., 2007].  s. Cerevisiae has often been 
used as a model for the mammalian analogue, so has dTOR from Drosophila 
melanogaster (fruitfly).  
mTOR is made of 2549 amino acids and contains 20 tandem HEAT repeats in the N 
terminus. Each HEAT repeat contains 2 α helices with both hydrophobic and 
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hydrophilic residues. mTOR contains in a downstream order of; a FAT domain (FRAP, 
ATM, TRAP), FRB, a kinase domain, a negative regulatory domain (NRD) and a FATC 
domain in the C-terminal half. The TOR kinase is a highly conserved, central controller 
of cell growth and may be involved in more proteins than those described below 
[Hay and Sonnenberg, 2004]. FRAP is another name for mTOR. 
 
Figure 3 the primary structure of mTOR with the 20 HEAT repeats, the FAT domain (FRAP, ATM, TRAP), FRB 
(FKBP12 rapamycin-binding), kinase domain, NRD (negative regulatory domain) and the FATC domain 
(another FAT domain) [Hay and Sonnenberg, 2004]. 
 
Both mTOR complexes are composed of mTOR and mLST8/GβL. GβL (G-protein β-
subunit like protein) is now most commonly referred to as mLST8, which is a 
mammalian ortholog to LST8 from s. Cerevisiae. However the two TOR complexes 
differs in some proteins and therefore they are regulated by different signals and 
drugs.  
One of the differences is a protein called either Raptor (regulatory associated protein 
of mTOR) in mTORC1 or Rictor (rapamycin-insensitive companion of mTOR) in 
Rapamycin-insensitive complex [Sarbassov et al., 2005a].  Whether Rictor is affected 
of rapamycin or not, will be presented in the mTORC2 section. 
Upstream of mTOR 
Two of the main components upstream of mTOR is the TSC1/2 complex and Rheb 
(Ras homolog enriched in brain). TSC (tuberous sclerosis complex) 1 and 2, is also 
known as hamartin and tuberin. The TSC heterodimer is a GTPase activating protein 
that inhibits Rheb. Rheb, is member of the Ras superfamily and a small GTPase. Rheb-
GTP binds and activates mTORC1. Akt phosphorylates and inactivates TSC2, whereas 
AMPK (AMP activated protein kinase) phosphorylates and activates TSC2 [Thedieck 
et al., 2007] 
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Figure 4 Pathway of mTOR and the substrates involved. PI3K activates Akt through PDK1. The TSC1/2 complex 
functions as a key negative regulator of mTOR and TSC1/2 is inhibited by Akt. Rheb is downstream of TSC1/2 and 
stimulates S6K1 and 4E-BP phosphorylation through mTORC1. S6K1 is involved in a feedback loop, which suppress 
the Akt pathway by inhibiting IRS (insulin receptor substrate). Rapamycin blocks mTORC1 directly [Hall et al., 2005]. 
Rapamycin also blocks mTORC2 (not shown). Some novel substrates are not shown on the picture but explained in 
the theory section. 
2.4.1 mTORC1 
mTORC1 (The mammalian TOR complex 1) is composed of mTOR, Raptor, mLST8/GβL 
[Sarbassov et al., 2004]. A novel component; PRAS40, has recently been associated 
with mTORC1 [Oshiro et al., 2007, Thedieck et al., 2007]. This complex functions as a 
nutrient/energy/redox sensor and a controller of protein synthesis. mTORC1 is 
activated by nutrients (amino acids),  anabolic growth factors (such as insulin and 
insulin-like growth factor), hormones and cellular energy (ATP) [Jacinto et al, 2006, 
Hay and Sonnenberg, 2004] and inhibited by low nutrient levels, growth factor 
deprivation and reductive stress. Moreover mTORC1 is inhibited by a range of drugs 
including rapamycin [Jacinto et al, 2006] and curcumin (which is found in for 
example turmeric, where the yellow colour is a result of the polyphenol curcumin/ 
diferuloylmethane) [Beevers at al., 2006]. mTORC1 controls transcription, protein 
synthesis, ribosome biogenesis, nutrient control and autophagy [Hay and 
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Sonnenberg, 2004]. Growth factor signals and energy status are transmitted to 
mTORC1 through TSC1/ 2. PI3K is also involved in mTORC1.  
2.4.1.1 Raptor 
Raptor was first found in s. Cerevisiae and was named KOG-1 (kontroller of growth-1) 
and has been identified as a positive regulator of TOR, because s. Cerevisiae with the 
phenotype KOG-1- resembles cells lacking TOR or rapamycin-treated cells [Loewith et 
al, 2002]. Raptor, consist of a conserved region in the N-terminal half, found in all 
Raptor othologs.  Hereafter there are 3 HEAT repeats and 7 WD-40 repeats in the C-
terminal half. WD-repeat proteins are a large family found eukaryotes and are 
implicated in a variety of functions including:  Signalling, transcription, cell cycle and 
apoptosis. WD-40 repeats are short amino acid motifs (about 40 amino acids long), 
often terminating in a Trp-Asp (W-D) dipeptide.  
The 20 HEAT repeats in the N-terminal of mTOR binds with Raptor, but the C-terminal 
of mTOR can also bind to Raptor, although this bonding is weaker. During nutrition 
deprivation mTOR-Raptor inhibits further mTOR activity [Kim et al, 2002]. The Raptor-
mTOR complex has shown to positively regulate cell size and a number of processes 
including mRNA translation [Richter et al., 2005], ribosome biogenesis [Hannan et al., 
2003], nutrient metabolism [Peng et al., 2002] and autophagy [Meijer and Codogno 
2004]. Inhibition of the complex has shown to cause decrease in size. When mTORC1 
is activated, S6K1 (p70-S6 Kinase 1) and 4E-BP1 (the eukaryotic initiation factor 4E 
(eIF4E) binding protein 1), becomes phosphorylated. S6K1 and 4E-BP1 are 
downstream regulators of mTOR, which increases protein synthesis [Jacinto et al, 
2006]. Both Raptor and mLST8/GβL are positive regulators of mTORC1 activities.  
2.4.1.2 PRAS40 
PRAS40 (proline-rich Akt substrate of 40 kilodaltons), is an upstream negative regulator 
of mTORC1. It binds to mTORC1 via Raptor, but requires mTOR kinase activity. The 
PRAS40 phosphorylation may contribute to the mTORC1-interaction. PRAS40 inhibits 
mTORC1 autophosphorylation and mTORC1 kinase activity towards S6K1 and 4E-BP1 
[Thedieck et al., 2007, Oshiro et al., 2007]. 
mLST8/GβL 
mLST8/GβL interacts with the kinase domain of mTOR (see Figure 3), independently of 
Raptor and plays a positive role in mTOR activation by nutrients. It has been shown 
that mLST8/GβL stabilizes mTOR-Raptor and it is therefore likely that mLST8/GβL, Raptor 
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and mTOR comprise a nutrient-sensitive complex and that mLST8/GβL regulates 
mTOR-Raptor stabilization under different nutrient conditions [Kim et al, 2003]. 
However studies have shown that rapamycin induces mTOR-Raptor dissociation but 
amino acid deprivation does not alter mTOR-Raptor association [Oshiro et al., 2004]. 
mLST8 is also a substrate of mTORC2. 
2.4.2 Downstream of mTORC1 
S6K1 was the first component of the pathway to be identified and despite it has been 
well studied, exactly how S6K1 regulates cell size remains still unclear [Sarbassov et al., 
2005a]. 
S6K1phosphorylation state is a convenient measure of the activity of the Raptor 
branch of the pathway [Sarbassov et al., 2005a]. mTORC1 phosphorylates S6K1 in the 
hydrophobic motif, which stimulates the subsequent phosphorylation of S6K1 by PDK1. 
Active S6K1 can stimulate the initiation of protein synthesis. Mice lacking S6K1 have 
small cells [Pende et al., 2004]. Most mammalian cells becomes more reduced in size 
by rapamycin than by S6K1 inhibition, indicating that more growth regulators must 
exist downstream of raptor. [Kim et al, 2002]. S6K1 can also participate in a positive 
feedback loop with mTORC1. 
Opposite S6K1, the role of 4E-BP1 is better understood.  When 4E-BP1 is in its non-
phosphorylated it represses the cap-dependent mRNA translation by binding to the 
translation initiation factor eIF4E. eIF4E is a cap-binding protein which interacts with to 
the  eIF-4G protein. Upon phosphorylation by mTORC1, 4E-BP1 releases eIF4E, allowing 
it to restore cap-dependent translation and will no longer inhibit the binding of mRNA 
to 4E-BP1 [Sarbassov et al., 2005a]. 
Both S6K1 and 4E-BP1 are downstream effectors of mTOR and recruited by Raptor. 
The interaction is mediated by the TOS motif (TOR signalling) which is found in the N 
termini of both S6K1 and 4E-BP1 [Kim et al, 2002] and is a conserved shorts sequence. 
Raptor recognizes the TOS motif, which is required for efficient phosphorylation 
[Sarbassov et al., 2005a]. Rapamycin inhibits the mTOR-Raptor interaction and results 
in non-phosphorylated S6K1 and 4E-BP1 [Kim et al., 2002]. 
The lack of conservation between S6K1 and 4E-BP1 phosphorylation sites and the high 
frequency of TOS-motif-like sequences in many proteins makes identification of mTOR 
substrates difficult. S6K1 and 4E-BP1 seems to be direct substrates of raptor-mTOR 
[Sarbassov et al., 2005a]. 
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2.4.3 mTORC2 
mTORC2 (The mammalian TOR complex 2) is composed of mTOR, Rictor/mAVO3 and 
mLST8/GβL [Jacinto 2004/Sarbassov 2004] and newly discovered proteins named 
mSIN1/MIP [Jacinto et al., 2006] and the mTORC2 associated protein, PRR5L/Protor 
[Woo et al., 2007]. TORC2 in s. Cerevisiae contains TOR2, LST8, AVO1, AVO2, AVO3 
and BIT61 [Loewith et al., 2002]. AVO3 is the ortholog of Rictor. AVO1 might be related 
to hsin1 (human stress activated protein kinase interacting protein 1), because of 
theirs functional similarities [Loewith et al., 2002].  
mTORC2 seems to respond to growth factors, possibly via TSC1/2 [Yang et al., 2006]. 
Biochemical studies has shown that mTORC2 is able to phosphorylate Akt at ser473 in 
the hydrophobic motif and thereby activates Akt toward substrates such as FOXO 
and BAD [Hresko and Mueckler, 2005, Sarbassov et al., 2005b, Jaquinto et al., 2006]. 
mTORC2 is futhermore involved in actin cytoskeleton reorganization and via Rho-
family  small GTPases and PKCα (protein kinase C) (described in the morphology 
section), which thereby determines cell shape and maybe the mobility of the cell 
[Jaquinto et al., 2004]. The actin cytoskeleton-regulation by Rictor-mTOR may still 
involve unknown mechanisms [Sarbassov et al., 2004, Jacinto et al., 2004]. It has been 
shown that mTORC2 directly phosphorylates Akt at hydrophobic motif site Ser-473 
[Sarbassov et al., 2005b]. 
2.4.3.1 Rictor 
Rictor is less studied than Raptor, mainly because it can not bind FKBP12-rapamycin 
and the discovery happened later. It is unclear why FKBP12-rapamycin does not bind 
the Rictor-cointaning mTOR complex. It might be Rictor or another component of 
mTORC2, which blocks the binding site [Sarbassov et al., 2005a]. 
 The findings leading to the discovery that it is Rictor-mTOR, which is the hydrophobic 
motif kinase of a rapamycin-resistant mutant of S6K1 (and not Raptor –mTOR) led to 
the discovering of a substrate of Rictor-mTOR [Ali and Sabatini, 2005]. This led to the 
realization that it is Rictor-mTOR, who is the hydrophobic motif kinase for Akt and plays 
an important role in Akt activation [Sarbassov et al., 2005b]. 
The Rictor-mTOR has previously been regarded as rapamycine-insensitive; however 
recent studies have shown that this is not entirely true. The mTORC2 complex does not 
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interact with FKBP12-rapamycin and is in this matter not affected by rapamycin. 
Sabatini et al. have showed that prolonged rapamycin treatment (more then 24h) 
inhibits mTORC2 assembly and thereby phosphorylation and activation of Akt. 
Although there results varied from cell type to cell type, they showed that Rictor 
decreased after 24 hours. They explain it with the newly synthesized free mTOR and 
the mTOR complexes turnover, which binds to rapamycin-FKBP12, preventing the 
subsequent binding of Rictor. They tested a variety of cell lines and found highly 
sensitive, partially sensitive and insentive cell lines. The sensitivity could be due to their 
in kinase activity toward Akt [Sarbassov et al., 2006].  
 
Figure 5 (A) shows the effect of prolonged treatment with 100 nM rapamycin in two different cell lines; HeLa and 
PC3. HeLa is a cervical cancer line and PC3 is a prostate cancer cell line. Samples were taken before treatment 
and at 0.5, 1, 2 and 24 hours after rapamycin-treatment. IP is short for immunoprecipitate. Raptor decreases 
immediately and can not be seen after half an hour. Rictor is absent after 24 hours.  (B) Here samples are also 
taken after 48 and 72 hours, Rictor-inhibiton is most profound in PC3 cells [Sarbassov et al., 2006] 
2.4.3.2 SIN1/MIP1 
SIN1/MIP1 is protein recently associated with mTORC2. It has been shown that SIN1 
regulates the Akt pathway, by phosphorylating Akt-Ser473 and thereby activating the 
Akt [Jacinto et al., 2006].Studies have shown that the SIN1-Rictor-mTOR complex is 
likely the principal if not the sole phosphoionsitide-dependent protein kinase 2 (PDK2) 
for Akt. In the absence of SIN1, phosphorylation of Ser473, but not Thr308 is abolished 
demonstrating that the PDK1-mediated Akt Thr308 phosphorylation is not dependent 
of a prior phosphorylation of Ser473 by PDK2 [Jacinto et al., 2006]. However another 
study has shown that both Ser473 and Thr308 phosphorylation of Akt was diminished in 
Rictor and mTOR knockdown cells [Sarbassov et al., 2005b].Futhermore, SIN1-/- cells 
have shown increased susceptibility to stress-induced apoptosis. SIN1 is not required 
for mTORC1, which have been indicated by the observation that TSC2 is 
phosphorylated normally in SIN1-/- cells and that SIN1 knockout and knockdown cells 
have an enhanced S6K1 phosphorylation at Thr389 [Jacinto et al., 2006].  
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Akt-Ser473 phosphorylation is not required for TORC1 activation, which can be due to 
the phosphorylation of Thr308 Akt fulfil this function or because Akt play a minor role in 
TSC2 phosphorylation. TSC2 is also phosphorylated and inactivated by other kinases 
such as AMPK, ERK1/2 and RSK at other sites than the Akt target. 
It is not clear if the SIN1-mediated TORC2 function involved the MEKK/MAPK 
cascades, but evidence suggests that the mTOR-Akt pathway is regulated by MAPKs. 
However Akt Thr308 and Ser473 phosphorylation is not affected in either MEKK2-
deficient or –activated cells, and MEKK2 do not interact with mTOR nor Rictor. 
However enhanced JNK and p38 activation are found in SIN1-/- cells, suggesting a 
parallel function of SIN1 in the MAPK pathway [Jacinto et al., 2006]. 
An interesting discovery is that mSIN1 exist in different isoforms and 3 of them 
assembles 3 different mTORC2s, indicating that the distinct mTORC2 isoforms 
phosphorylates Akt in response different substrates. The mSIN1 isoforms which 
assembled into mTORC2 were named mSIN1.1, mSIN1.2 and mSIN1.5. mSIN1.1 and 
mSIN1.2 showed to phosphorylate Akt in response to insulin [Frias et al., 2006]. The 
upstream regulator of mSIN1.5 has, to our knowledge, not yet been found. The 
prolonged effect on Rictor by rapamycin [Sarbassov et al., 2006], which is shown on 
Figure 5, also affects mSIN1.1 and mSIN1.2 after 24 hours when treated with 100 nm 
rapamycin. The two studies combined suggest that the novel discovery of mTORC2 
inhibition by rapamycin is a result of the short lived mSIN1 proteins affected by 
rapamycin [Frias et al., 2006]. 
2.4.3.3 PPR5L/ Protor 
PRR5L (Proline-rich protein 5-like) is another protein recently associated with mTORC2. 
PRR5L interacts with rictor , independent of mTOR. PRR5L, unlike mSIN1, is not 
important for the mTOR-Rictor complex assembly or for the mTOR activity towards Akt 
phosphorylation. Despite no significant effect of PRR5L on mTORC2-mediated Akt 
phosphorylation, studies have shown that PRR5 silencing inhibits Akt and S6K1 
phosphorylation and reduces cell proliferation.  The inhibition of Akt and S6K1 
phosphorylation by PRR5 knock down correlates with reduction in the expression level 
of platelet-derived growth factor receptor β (PDGFRβ). PRR5L silencing impairs PDGF-
stimulated phosphorylation of S6K1 and Akt but moderately reduces epidermal 
growth factor- and insulin-stimulated phosphorylation [Woo et al., 2007].  
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In another study, where HeLa and HEK293 cells were used, PRR5L binds to mTORC2 by 
SIN1 and/or Rictor. PRR5L was phosphorylated by both mTORC1 and mTORC2. The 
results suggested that PRR5L is not considered an mTORC2 upstream regulator or an 
integral component of mTORC2, but a downstream effector of mTORC2. PRR5L has 
also shown to promote apoptosis in a matter similar to TSC1/2 deficiency [Thedieck et 
al., 2007]. 
2.3 PI3K/Akt pathway 
Akt (also known as PKB (protein kinase B)) is a serine/threonine kinase, and is 
recognized as a primary mediator of the downstream effects of PI3K, making it a 
controller of responses to extrinsic stimuli. Akt is involved in a range of signalling 
pathways involved in cell proliferation, apoptosis, glucose metabolism or angionesis 
[Fulda and Debatin, 2006]. Akt is activated by growth factors, cytokines, hormones, 
neurotransmitters [Yang et al., 2004] and DNA damage. Following the p53 pathway, 
the PI3K-PTEN-Akt signalling pathway is one of the most mutated pathways 
associated with cancer [Parcellier et al., 2008]. Akt appears to be a substrate of 
mTORC2 [Hresko and Mueckler, 2005; Sarbassov et al., 2005b]. The role of Akt in 
rearrangement of cytoskeleton is still studied and novel components emerge 
frequently.  
 
Humans and mice have 3 isoforms of Akt, named Akt1, Akt2 and Akt3 (also named 
PKBα, PKBβ and PKBγ), whereas yeast, flies and worms only have one Akt protein. 
They are located on different genes but share 80 % amino acid identity and with only 
minor differences between man and mice [Yang et al., 2004]. By studies with knock-
out mice, the functions of the various Akt isoforms have been determined. Akt1 has 
been linked with placental development, growth and adipogenesis. Adipogenesis is 
the development of fat cells from pre-adipocytes.  Akt2 is involved in glucose 
metabolism, adipogenesis and maintenance of growth. Akt3 is located in the brain 
and has been linked with postnatal brain growth.  
This was illustrated by Akt1- mutants, who were smaller than wt mice, but without 
apparent defect in glucose homeostasis and often with apoptosis occurred 
spontaneously in thymus and testis. Akt2 null mice had impaired glucose metabolism 
shown as severe diabetes but without severe growth defects. Akt3 null mice have 
small brains, but neither growth defects nor impaired glucose metabolism. Double 
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knockout of Akt isoforms give different phenotypes; Akt1/3 double knockout mice are 
embryonic lethal, while Akt1/2 double knockout mice die soon after birth. [Yang et 
al., 2004, Kato et al., 2007].  
Akt requires three ordered processes to be activated:  
1. Translocation to the plasma membrane through PH domain binding to PIP3. 
2.  Phosphorylation of Ser473, which increases the kinase activity 10-fold and is 
necessary for Thr308 phosphorylation.  
3. PDK1 is recruited and activated by PIP3, thereby phosphorylates Thr308, 
resulting in a 100-fold kinase activity, which is a 1000-fold increase in total 
[Sasaki and Firtel, 2006].  
When Akt is stimulated, it activates PI3K (Phosphoinositide 3-kinase) through receptor 
tyrosine kinases, which recruits Akt to the membrane where Akt gets phosphorylated 
[Yang et al., 2004]. Akt possesses a kinase domain and a PH domain (pleckstrin 
homology domain), which binds to phoshoinositides, such as PIP2 
(phosphatidylinositol (4,5)-biphosphate) or PIP3 (phosphatidylinositol (3,4,5)-
triphosphate), with high affinity. When a receptor tyrosine kinase binds with growth 
factors, the receptor is phosphorylated which recruits PI3K to the plasma membrane. 
PI3K are classified into three classes based on its structure; class I PI3K is primarily 
responsible for PIP3 production due to extracellular stimulation. Class II is not well 
understood and phosphorylates PIP2 although only poorly. It is class II PI3K, which have 
been connected with resveratrol [Srivastava et al., 2005]. Class III PI3K regulates 
intracellular vesicle trafficking and have shown to be involved in mTOR activation in 
response to amino acids [Sasaki and Firtel 2006]. PI3K mediates PIP2 into PIP3, which 
leads to the recruitment downstream targets to the cell membrane and their 
subsequent activation [Parcellier et al., 2008], by PIP3 recruiting Akt to the membrane, 
where Akt becomes phosphorylated at thr308 and ser473, by the upstream kinases 
PDK1 (phosphoinositide-dependent kinase 1) [Yang et al., 2004] and mTORC2.  The 
identity of the kinase, responsible for Ser473 phosphorylation, have remained 
unidentified until lately [Hresko and Mueckler, 2005; Sarbassov et al., 2005b]. 
Knockdown of Rictor completely blocks Ser473 phosphorylation of Akt, however 
knockdown of Raptor enhances Ser473 phosphorylation, which could be explained 
by depletion of mTORC1 increases mTORC2. 
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PTEN (Phosphatase and Tensin homolog) is another important protein involved in the 
Akt pathway. PTEN is a tumor suppressor, which blocks Akt and thereby uncontrolled 
growth, by dephosphorylating PIP3.PTEN is normally localized at the plasma 
membrane but moves from the plasma membrane to the cytosol after 
chemoattractant stimulation. During chemotaxis, PTEN is excluded from the leading 
edge and becomes localized to the lateral sides and back of the cell 
Although the molecular mechanisms by which Akt and Girdin/APE regulate 
chemotaxis remain to be uncovered, the findings are particularly interesting because 
Girdin/APE maybe is the missing link between Akt and F-actin polymerization, and it 
may participate in the suggested feedback activation loop between Ras/PI3K and F-
actin 
 
Akt has been shown too been to be required for chemotaxis in mammalian 
leukocytes and dictyostelium (slime mould) [Chung et al., 2001]. A growing body of 
evidence indicates that Akt promotes cell motility in mammalian fibroblasts and 
tumour cells [Higuchi et al., 2001]. P13K and PTEN have been shown to be essential for 
cell migration [Merlot and Firtel, 2003]. Furthermore over expression of constitutively 
active Akt enhances cell migration. mTORC2 phosphorylates Akt,  which leads to the 
phosphorylation of Girdin/APE, leading to the formation of F-actin [Sasaki and Firtel 
2006].  
Girdin/APE 
Girdin/APE (girders of actin filaments/Akt phosphorylation Enhancer) binds to actin 
filament at the plasma membrane, whereas during cell migration, Akt-mediated 
phosphorylation allows Girdin/APE to localize at the leading edge and contribute the 
formation of short-branched filaments in the lamellipodia[Enomoto et al., 2005]. 
Girdin/APE contains an Akt phosphorylation site at the C-terminus and this is 
responsible for the localizing to the plasma membrane. Knockdown of Girdin/APE 
completely abolish cell motility. Girdin/APE represents the molecule missing between 
Akt and F-actin polymerization and may participate in a feedback loop between 
PI3K and F-actin [Sasaki and Firtel 2006].  
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2.5 Cell morphology 
 
Figure 6 F-actin polymerization. This model shows how F-actin assembles at the leading edge in a chemotaxing 
cell. The feedback loop from PIP3 involves TORC2, Akt-Girdin/APE, the WAVE/Scar complex and RhoGEF, Cdc42 
and WASP. The external stimuli are mediated through the chemoattractant which activates the G- protein βγ 
subunit (Gβγ). Gβγ induces F-actin polymerization, Cdc42 activation and PI3K activation through Ras [Sasaki and 
Firtel, 2006]. The proteins are described in the text below. 
2.5.1 Actin filaments  
The rearrangement of the cytoskeleton is a fundamental function seen in all 
eukaryotic cells from amoeba to advanced neural cells. Chemotaxis, or directed cell 
movement up a chemical play an essential role in a range of functions including: 
development, homeostasis, wound healing, cancer cell metastasis and moving 
towards food or away from toxicants in protozoa. Where an amoeba relies on F-actin 
assembly an adhesion receptor mediated migration has been found in higher 
developed cells including fibroblasts and myoblasts. This migration depends on 
adhesion receptor and/or cell-substrate interaction and creates a remodelling of the 
extracellular matrix [Sasaki and Firtel, 2006]. 
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Rearrangement of the cytoskeleton is central to the morphological changes. The 
amoeboid crawling system, which emerged about a billion years ago has been 
conserved through evolution from Dictyostelium (slime moulds) to leukocytes (white 
blood cells) and depends on cytoskeleton-mediated cell movement in which the 
assembly of a branched F-actin network provides movement.  
Actin filament is one of the three major components of the cytoskeleton. G-actin is 
small globular proteins forming helix filaments (F-actin). Actin filament has two 
dynamic structures; network and bundle structure. Lamellipodia is arranged in a 
network structure, whereas filopodia and stress fiber have bundle structures. Filopodia 
moves in one dimension, and lamellipodia moves parallel with substratum in two 
dimension. The net filaments of Lamellipodia can assembly at one end and move 
forward. The filaments can be seen as protrusions out of the cell, providing movement 
or as skeletal structure inside the cell, giving strength and stability to the cell [Alberts 
et al., The Cell]. 
When a cell is treated with a substrate, which binds to the receptors on the plasma 
membrane, the receptors convert it into an intracellular signal, making the cell 
undergo dynamic changes. This can cause asymmetric localization of the cellular 
components. Treatment with an F-actin polymerization inhibitor, such as latrunculin A, 
induces a rounded shape and cell immobilization [Sasaki and Firtel, 2006].  
2.5.2 Rho family of small GTPases 
The Rho family of small GTPases are key regulators of the actin cytoskeleton during 
chemotaxis. The most well known members are Cdc42 (Cell division cycle 42), Rac 
and Rho, which are present in all mammalian cells. Cdc42, Rac and Rho are 
responsible for the rearrangement of actin filaments. They act as molecular switches, 
which cycle between GTP-bound (guanosine-5'-triphosphate) and GDP-bound 
(guanosine diphosphate) states. When a Rho GTPase is in its GTP-bound state it is 
active, and inactive when GDP-bound [Alberts et al., The Cell]. This is regulated by 
GAP (GTPase-activating proteins), GEF (guanine nucleotide exchange factors) and 
nucleotide dissociation inhibitors [Sasaki and Firtel, 2006].  
Activated Rac and Cdc42 induce morphologically distinct actin protrusions at the 
membrane. Where the activation of Cdc42 induces filipodia-extensions, the 
activation of Rac makes the lamellipodia extend [Carryway et al., 1998] Mammalians 
have tree Rac isoforms; Rac1, Rac2 and Rac3. Rac1 is expressed throughout the 
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body, Rac2 is only expressed in hematopoietic cells and Rac3 is expressed in the 
developing nervous system and adult brain. 
 
Although the inhibition of Cdc42 does not block cell movement and pseudopodia 
formation, it suppresses persistent leading edge formation and induces non-
directional F-actin projection. Cdc42 can induce Rac activation by recruiting and 
activating of PAK (p21-activated kinase complex) and PIX (PAK-interacting protein). 
PIX have GEF activity toward Rac and Cdc42, see Figure 6. 
An important mediator for F-actin protrusions is the Arp2/3 complex (Actin-related 
proteins). Rac and Cdc42 induce protrusions through Arp2/3, which creates rapidly 
growing branched actin filaments, providing a mechanical force to move the 
membrane.  
Rac-Wave/Scar and Cdc42-WASP (Wiskott-Aldrich syndrome protein) both activates 
the Arp2/3 complex. WASP also relies on PIP2 to be activated but can also bind to PIP3 
and –SH3 containing molecules. WASP binds G-actin and Arp2/3, which makes Arp2/3 
to assemble the G-actin into F-actin. Recent studies have shown that most WASPs 
bind to member of the WIP proteins (WASP-interacting protein).  Another protein, 
Toca-1 (trans-inducer of Cdc42-dependent actin assembly) has been identified and 
shown to bind specifically to GTP bound Cdc42 and has furthermore shown to be 
essential for the neural Cdc42/WASP mediated F-actin polymerization. 
The WAVE /Scar genes are found in three places in mammalians and named WAVE1, 
WAVE2 and WAVE3. The expression of WAVE1 and -3 are mainly expressed in the 
brain, whereas WAVE2 are found everywhere. WAVE/Scar knockdown cells have 
significantly reduced lamellipodial formation. Rac binds to PIR121, causing WAVE-
mediated Arp2/3 activation. Cdc42 and Rac are only activated at the leading edge. 
The activation of Rac is achieved by a chemoattractant-mediated activation of 
RhoGEF. The human genome contains more than 60 RhoGEF and many of those are 
activated due to PIP3 production [reviewed in Sasaki and Firtel, 2006]. 
 
2.5.2 Regulation of cytoskeleton  
The role of mTORC1 in actin rearrangement is not yet clear [Jacinto et al., 2004], but 
the upstream negative regulator, the TSC1/2 complex can induce actin 
rearrangement by Rho GTPases and induces Rac activation. TSC1 activates RhoA 
and induces stress fibers [Sasaki and Firtel, 2006]. Knockdown of the Raptor (in 
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fibroblasts) does not cause a detectable defect of the actin cytoskeleton [Jacinto et 
al., 2004]. 
One of the major roles of mTORC2 is rearrangement of the actin cytoskeleton. 
Formation of stress fiber and lamellipodia caused by activation of Rho and Rac has 
been observed in NIH 3T3 cells (a fibroblast cell line), which suggests that mTORC2 
may signal to the actin cytoskeleton through Rho and Rac. Rho and Rac are 
downstream substrates of mTORC2 and when mTORC2 is blocked, they are 
activated. (Figure 4) [Jacinto et al., 2004].  
Another study of HeLa cells suggests that mTORC2 signals actin cytoskeleton through 
PKCα (Protein Kinase C α), which is also downstream of mTORC2. This is consistent with 
the studies in S. cerevisiae which demonstrate that TORC2 controls cell polarity 
through a PKC-Rho GTPase pathway [Sasaki and Firtel, 2006]. The activation of PKCα 
is reduced in Rictor and mTORC2 knock-down cells [Sarbassov et al., 2004].   
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Only few studies have been published regarding resveratrol and cell morphological 
changes in the cytoskeleton. Scientists have observed that resveratrol significantly 
affects the shape of endothelial cells in vitro, changing the cells from a cobblestone-
like appearance (Figure 7 A) to an elongated shape with long protrusions (B) [Bruder et 
al., 2001]. 
 
Figure 7 Resveratrol treatment produces elongation of BPAEC (Bovine pulmonary artery endothelial 
cells).  (A) Example of stellar, cobblestone-like morphology characteristic of normal BPAECs grown in 
vitro.  (B) Example of elongated, spindle-shaped morphology characteristic of resveratrol treated cells. 
The cells were treated with 100 µM resveratrol and were viewed with 20X objective [Bruder et al., 2001].  
 
2.6 AFM  
Atomic force Microscope (AFM) was invented by Binning and colleagues in 1986 
[Binning G et al., 1986]. The AFM was invented to scan solid materials and have later 
showed to be useful for biological samples. The soft structure of for example a cell or 
bacteria can thereby be problematic, when the tip (probe) of the cantilever 
interacts with the sample, altering the structure. The tip of the AFM interacts with the 
sample either in a very close distance or in contact with the surface of the sample. 
The interaction is named probe-sample interaction. The local probe is a sharp tip, with 
a radius around 10 nm, and with a stretched pyramid-like structure. During optimal 
conditions the interaction is only between the outermost atom of the tip and a single 
atom on the sample [Morris et al., 1999; Güntherodt and Wiesendanger, 1994]. 
Therefore very small structures and objects can be seen in AFM.  
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Figure 8 Example of a scanned cell with AFM in DC-mode (contact) in liquid showing cytoskeleton 
fibers of a live osteoblast [Lehenkari et al., 2000]. 
Optical detection method in AFM 
There are several modes for detecting tip sample information in AFM. The most 
common method is the optical detection method. In the optical detection method, 
a laser beam hits the back of the cantilever and is reflected to a photodetector, 
which is an array of photodiodes. The photodetector records the surface information. 
The tip-sample interaction causes a deflection of the cantilever, which is monitored 
by the photodetector, recording information of the x,y and z-scale of the sample, 
thereby giving a true three-dimensional image [Morris et al., 1999]. 
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Figure 9 Principle of optical detection method in atomic force microscopy (AFM) and the interaction 
between the tip and the sample. The laser beam is reflected to the photodetector, recording changes 
in the surface which is mediated through the tip and cantilever. The enlarged picture of the atoms of 
the tip and surface, illustrates the repulsive forces between the two objects [sdu.dk/visualisering]. 
 
DC and AC mode are two different modes used with AFM. We have only used AC 
mode but both modes are described to illustrate the differences and to give some 
background information.  
DC Mode 
In DC-Mode, the tip is in contact with the sample during scanning. The cantilever tries 
to maintain a constant deflection during the scan. The constant deflection is equal to 
a constant interaction force. However, as the height of the surface changes, the 
forces of the two surfaces changes too, making the interaction change leading to 
the change of the deflection. The photodetector records these changes [Morris et al., 
1999]. 
When scanning in air a thin water layer might be present on the sample surface. The 
capillary forces will make the water adhere to the tip adding to the shear force 
already present by scanning the tip in contact with the surface [Braga and Ricci, 
2004]. Biological samples are often sensitive to shear force and the alternate, AC-
mode where shear force is negligible, is therefore often used as an alternative.  
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Figure 10 Interaction between the tip and sample in AC-Mode. The picture illustrates compulsive forces 
between the point of the tip and outer nuclear layer of a sample [Chem.ox.uk]. 
AC-Mode 
The AC-mode has no direct contact with the sample or only intermediate contact 
with the sample, therefore, AC mode effect biological sample less, when compared 
with DC-mode. In AC-mode a shaker mechanism oscillates the cantilever at its 
resonance frequency. When the tip, at the end of the cantilever, comes in 
intermediate contact with the sample the amplitude of the generated oscillation is 
dampened. The degree of dampening is equivalent to the force interaction between 
tip and sample. Scanning the sample surface the amplitude of the oscillating 
cantilever changes in accordance with sample height. The scanner compensates 
the change in amplitude, moving towards or away from the sample, maintaining 
constant amplitude [Morris et al., 1999; Braga and Ricci 2004].  
The technique of scanning in liquid has been developed both in DC-mode and AC-
mode. However the procedure of scanning biological samples in liquid is still under 
development [Morris et al., 1999]. Thus, it is so far, more reliable to scan biological 
samples in air combined with some fixation. 
There are many different fixation techniques, we chose the fixation with 
glutaryldehyde and osmium tetroxide, because it seems to affect the samples less 
and have been used before at our institute (as well as others) making comparison to 
prior experiments easier.   
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3. Materials and Methods 
3.1 Culture Medium, chemicals etc. 
McCoy’s 5A media w. GlutaMAXTM (10 % FBS), D-PBS, Gemtamicin and Trypsin (from 
Gibco). Resveratrol, Rapamycin and poly-L-lysine were from Sigma-Aldrich. NaOH 
(highest grade available). 
The chemicals used to the fixation; Glutaraldehyde 25%, Osmium tetroxide(s) and 
sodium cacodylate were obtained from Electron Microscopy Science, all EM grade. 
NuncTM  culture flasks. Cover slips (Knittel Gläser, Germany). 10 cm NuncTM Petri dishes. 
10 cm Petri dishes (glass). Parafilm (Pechiney Plastic Packaging Company). 
Resveratrol Stock solution: 600 mM resveratrol, dissolved in DMSO, stored at -18°C, and 
diluted to 60 µM for the experiments. Rapamycin was diluted to 0.5 µM. Poly-L-lysine 
500 µg/ml dissolved in MilliQ-water, stored at -18 °C.                             
3.2 Instruments and Software  
DME Dual scopeTM DC 95-50, Dual ScopeTM C-21. Dual Scope/RasterscopeTM version 
1.4.1.12. DME-SPM software version 5.03.2600.2180 was used for analyze the cells and 
to measure the height. Scan conditions: AC mode was used throughout the project, 
force 0.1–0.15 nN, scan speed 30-80 µm/s, resolution from 128×128 to 512×51.2. Range 
from 50×50 to 200×200 µm. 
ImageJ version 1,38x was used to measure cell size. Cantilevers (Nano World 
Pointprobe) glued on Dual ScopeTM Plug and Play mounting rings. The cantilevers 
where pyramidal in shape with the measurements of; 120-130 µm in length, 25-35 µm 
in width and 3.5-4.5 µm thick..  
Phase contrast Microscope Leica DM IRA witLeica DC 300F cam. Coulter counter: 
Coulter® Partikle count & size analyser Z2 (Beckmann Coulter Inc.) Software: Multisizer 
program AccuComp.  Osciliscope used for measuring the resonance when working 
in AC-mode.   
3.3 Cell line and cultivation  
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The Cells used in this work were derived from Human colon epithelia colorectal 
adenocarcinomas, DLD-1  (American Type Culture Collection , and were cultured in 
NuncTM culture flask (75 cm2) in 5a McCoy media with 10% FBS serum and Geneticin 
and held at 37°C, 95 % humidity and 5 % CO2. The cells were subcultured twice a 
week, and cells used for the experiments were 50% to 80% confluent. Cells used for 
experiments were counted in Coulter Counter and kept on ice.  
3.4 AFM Sample Preparation  
Before attachment of the cells, cover slips were marked with a glass cutter so specific 
single cells later on can be identified.  The cover slips were then incubated with 2M 
NaOH for 2 hours so the poly-L-lysine can stick to the cover slips better. The cover slips 
were coated with 500µg/ml poly-L-lysine for 10 to 15 min so that the cell can attach 
more easily to the glass surface. After incubation with poly-L-lysine, the cover slips 
were washed twice with MilliQ, sterilized in 70% ethanol and washed in PBS once. They 
were then transferred to sterile petri dishes for further usage. The poly-L- lysine coated 
cover slips was placed in 10 cm sterile petri dishes and a cell suspension containing 
around 6400 cells/cm2 in 12 ml medium The cell suspension was obtained by 
trypsination of the growing cell culture and kept on ice during counting to avoid cell 
aggregates, 10 ml of the cell culture are transferred to a 50 ml NuncTM tube with 20 ml 
media in on ice. The cells, which normally attach to the surface of NuncTM tubes, were 
not able to attach when they are stored on ice. Samples from the NuncTM tube are 
were transferred to the coulter counter to determine the cell concentration. Each 
petri dish ends up with a density of 6400 cells/cm2, which in our case is 500 000 cells in 
12 ml. The cells attached to the cover slips overnight. 
3.5 Resveratrol and rapamycin treatment  
The cells attached o the cover slips with cells were washed twice with PBS and 
transferred to new sterile petri dishes. By transferring the cover slips to new petri 
dishes, only the cells attached to the cover slips would be further treated. Two or 
three cover slips were prepared for each treatment at both 48 and 72 hours.  New 
media containing resveratrol, rapamycin, a combination or a control, were added 
into petri dishes. 
Three experiments have been performed. In experiment 1, cells were treated with 
0.1% DMSO (control) or 60 µM resveratrol for 48 and 72 hours treatment. In the 
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following two experiments, the cells were treated with:  0.1% DMSO (control), 60 µM 
resveratrol, 0.5 µM rapamycin or 60 µM resveratrol and 0,5 µM rapamycin  for 48 and 
72 hours treatment.  
After 48 or 72 hours of incubation, phase contrast pictures were prepared using Leica 
microscope with a 200x magnification. Then, the cells were fixed and dehydrated for 
AFM scanning (method described below). If not scanned immediately, cells were 
stored in petri dishes, wrapped in Parafilm at 4°C. The best pictures were obtained by 
taking the pictures before the old medium was removed. Ethanol (after fixation) 
changed the focal point and to long exposure in PBS stressed the cells.  
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3.6 Fixation with glutaraldehyde and osmium tetroxide 
When cells were treated with glutaraldehyde, the cells are quickly killed as 
glutaraldehyde cross-links the cellular proteins. Glutaraldehyde has two aldehyde 
groups, separated by a flexible chain of 3 methylene bridges and its chemical 
formula is HCO-(CH2)3-CHO. It can form polymers (Figure 11). There is a free aldehyde 
group sticking out of the side of each unit of the polymer molecule, as well as one at 
each end. All these -CHO groups will combine with nitrogen in for example proteins 
(Figure 12). In this way, the proteins in the membrane and the inside of the cell are 
fixed [Kiernan, 2000]. 
 
Figure 11 (A) Three representations of a molecular structure of glutaraldehyde: Two aldehyde groups –CHO 
connected by 3 ethylene group.  (B) Glutaraldehyde form polymers, an aldehyde side-chain is on each unit of the 
polymer [Kiernan, 2000]. 
Secondly, osmium tetroxide was used to react with the lipids, as well as stabilize cell 
membrane and membranes of organelle, and to insolubilise proteins without 
coagulation. Osmium tetroxide reacts with the membrane-bound proteins, and is 
kept in the cell during this fixation [Glausert, 1975].  
 
 
 
 
 
 
Figure 12 The mechanism of poly-
glutaraldehyde reacting with protein.  
Poly-glutaraldehyde cross linked with 
nitrogen in amino groups of proteins 
[Kiernan, 2000]. 
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The fixation is followed by dehydration in ethanol and acetone. Ethanol and acetone 
were added with increase concentration slowly without collapsing the whole cell. In 
this way, it was able to measure the height of the cell in order to investigate the 
effect of resveratrol and rapamycin on cells [Glausert, 1975].  
 
The Preparation and the procedure of the fixation and dehydration  
Sodium cacodylate buffer: 0.2 Sodium cacodylate dissolved in MilliQ-water to 0.1 M.  
Glutaraldehyde solution: 1.58ml 25 % glutaraldehyde + 8.42ml MilliQ-water + 0,2M 
10ml sodium cacodylate buffer.  The sodium cacodylate solution is 0.1 M and the 
glutaraldehyde is 2% during the fixation. 
Osmium tetroxide solution: 0.25g osmium tetroxide was dissolved in 25ml 0.1M sodium 
cacodylate buffer at least 30 min before usage and was vigorously shaken with the 
whillmix to dissolve it.  
After washing with PBS, the cover slips were placed in plastic petri dishes in primary 
fixative (2% glutaraldehyde in 0.1M sodium cacodylate buffer), for 120min at 4°C after 
which they were washed twice in 0.1M sodium cacodylate buffer for 30min at 4°C.  
The secondary fixation was done using 1% osmium tetroxide in 0.1M sodium 
cacodylate buffer for 90min at 4°C (glass dishes) as the osmium tetroxide can react 
with plastic, and this step was followed by three time wash in MilliQ for 5min at room 
temperature (RT). 
Dehydration of the samples were done by exchange the water with ethanol  and 
then acetone (the cover slips should be covered by the solutions): 25% ethanol for 15 
min, (RT); 50% ethanol for 15 min, (RT); 75% ethanol for 15 min, (RT); 96% ethanol for 15 
min, (RT); 96% ethanol for 30 min (RT); 1/3 acetone in 2/3ethanol for 15 min (RT); 1/2 
acetone in 1/2 ethanol for 15 min (RT); 2/3 acetone in 1/3 ethanol for 15min (RT); 100% 
acetone for 15 min (RT). Lastly, acetone was removed, the samples were left in fume 
hood to dry, and were transferred to new petri dishes. If not scanned immediately the 
samples were kept dry and refrigerated. (The fixation technique was kindly provided 
by Nadja Møberg from Copenhagen University). 
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3.7 AFM Scanning 
The samples where transferred to the scanner stage, with the cell side up and fixed to 
the stage with a single drop of ethanol under the cover slip to avoid any movement 
or sliding of the cover slip. The crosses in the cover slips are found compared with the 
pictures from the phase microscopy. The function AC (tapping) mode was used 
through the entire project with retrace signal turned on. Oscillation frequency and 
amplitude were observed during scan. The cells were scanned at a minimum of two 
or three times, and the scans are saved. Scan speed or force was reduced when a 
shrieking sound occurred. Abrupt shifts in height seemed to induce shrieking. Shriek is 
a phenomenon, which occur when the resonance is not calibrated, which can be 
measured on the oscilloscope and the parameters changed in the DME software.     
Plane correction was used to optimize the later analysis. An effect called “eye 
balling” occurs when the fixed arm of the cantilever scans the cells. The artificial 
elevated corners are flattened, which is necessary for area and height 
measurements. 
DME-SME 
DME-SPM was used to analyze the scanned cells and measure the heights. The 
program was used to obtain clear images of the cell outline. By adjusting the light 
bar, one can get a more detailed picture of either the top or bottom of the cell. 
When the light bar was lowered, the nucleus is pictured as a bright but blurred 
structure. However, the edge of the lamellipodia and the filopodia, become clear 
and more detailed. If the color bar is at maximum, the details of the actin filaments 
become blurred and hard to distinguish from the surface of the poly-L lysine treated 
cover slip. Instead the nucleus gets richer in details. The colors (Californian sunset) 
seen in the AFM scans, are used instead of a gray scale because the height 
difference becomes clearer. 
ImageJ 
ImageJ was used to calculate the area of the cells, by framing the cell along the 
lamellipodia and the filopodia. This is done by ImageJ by counting pixels. The 
program need the information of length and height of the picture, which are written 
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in the lower right and in the upper left respectively, of the pictures below. Figure 1 
show examples of framed cells and the calculated cell size. The examples show the 
drawn lines and the calculated size. All examples are from the experiment after 48h 
of exposure.  All the cells scanned by AFM from experiment 2 and experiment 3 were 
measured. 3 to 6 measurements were made for each treatment.  High resolution 
pictures were used because the low-resolution AFM images made the analysis more 
difficult and less precise.  
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4 Results 
4.1 phase contrast images 
The pictures obtained by the phase contrast microscope before the fixation and 
dehydration procedure are interesting because they show the differences of the two 
microscopes and before/after fixation and dehydration. The phase contrast pictures 
also give an impression of the general cell structure in the various treatments. 
The control cells have less pronounced protrusions compared to the resveratrol-
treated cells. The typical resveratrol cell has the appearance of a fried egg; a 
rounded shape and tend to extend in size compared with the control. However we 
have also observed astrocyte-like cells; less cytosol and long protrusion. The peaks of 
the nucleoli appear as black dots in the phase contrast (can be seen in b) resveratrol 
and d) resveratrol plus rapamycin, in Figure 13). These upright protrusions with 
microvillus-like appearance have been described in previous studies [Kristoffersen, 
2006]. The shape of the rapamycin-treated cells looks similar in shape to the control 
cells. The cells treated with the combination, both have the rounded shape cells, 
seen in the resveratrol-treated cells and other cell shapes as well. 
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a) Control b) Resveratrol 
 
 
c) Rapamycin d) Resveratrol + rapamycin 
Figure 13 Pictures taken with the phase contrast microscope with 20 times magnification, in experiment 
3 after 48 hours of incubation. The crosses are the man-made identification marks used for to find the 
same single cells in the AFM. 
Picture after the fixation were also taken by the phase contrast (not shown), to see 
the effect of the fixation to the cells. They look more crystal-like but not with any 
visible different morphology regarding the protrusions compared to the AFM scans. 
4.2 Area 
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The scanned DLD-1 cells from the AFM were analyzed with the help of DME-SPM and 
ImageJ to obtain cell size and height. Morphology changes were also observed using 
visual inspection.  
Examples of analyzed cells are given in Figure 14 and Figure 17, and data are obtained 
for analyzing 3-6 measurement for each treatment, time and experiment.  
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 As showed in Figure 16, resveratrol treated cell has the biggest area, whereas the 
treated combination cell also trends to increase in size. However, the rapamycin-
treated cells do not appear to increase in size.
 
A) Control 
 
B) Resveratrol 
 
C) Rapamycin  
 
 
D) Resveratrol + rapamycin 
 
  
Figure 14 Examples of determination of cell area of DLD-1 cells by ImageJ. Cells was exposed, for 48 h, 
to DMSO (Control) (A), 60 µM Resveratrol (B), 100 nM Rapamycin and 60 µM Resveratrol (C), or 100 nM 
Rapamycin (D). Area of the cells: 705 (A), 4781 (B), 3970 (C) and 778 (D) µm2.  
 
The nucleus of the resveratrol-treated cells tends to increase in size too, as illustrated 
in the pictures below. This has previously been observed (Stervbo et al. 2006B].  
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Nucleus size of DLD-1 cells is increased by resveratrol. Cells was exposed, for 48 hours, to 
DMSO (Control) (A) or 60 µM Resveratrol (B) with a nucleus size of 343 µm2 and 1537 µm2 respectively. 
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Figure 16 Effect of resveratrol and rapamycin on the cell area of DLD-1 cells. The numbers are an 
average of two experiments ±STD following exposure to 60 µM resveratrol and 0.5 µM rapamycin. 
Treatment of cells, fixation and AFM scanning was done as described in the material and method 
section. The mean area of control cells at 48 h and 72 h were 805±151 µm2 and 907±179 µm2, 
respectively. 
4.3 Height 
 
A) Control 
  
B) Resveratrol 
C) Rapamycin 
D) Resveratrol + 
rapamycin 
  
Figure 17 Examples of height determinations in 4 single cells exposed to DMSO (control), resveratrol, 
rapamycin and resveratrol plus rapamycin. All the examples are after 72 hours of treatment in 
experiment 3. The height of nucleoli, nucleus, and cytosol and lamellipodia were draw by black, 
brown, fuchshsia (purple) and green respectively. The red line is the overview of the cell height. All the 
cells scanned by AFM from experiment 2 and 3 were drawn using this technique (3-6 measurement for 
each treatment, time and experiment).  The edges between the different cell parts can be difficult to 
distinguish, but adjusting the light bar and flattening the edges helps this. 
The untreated cells have the highest structures with a more soft hill-like structure, 
whereas the resveratrol-treated cells seem to collapse in especially the nucleus and 
have a more rigid cortex compared to the untreated. The Rapamycin-treated cells 
have also lower heights than untreated cells but not the rigid cortex appearance of 
the cells incubated with resveratrol. The cells treated with the combination are higher 
than the resveratrol-treated cells.  
  
  
Figure 18 height of nucleoli, nucleus, and cytosol and lamellipodia in nm. The four columns in each 
figure represents the measured height after 48 and 72 hours treatment of DMSO (control), 60 µM 
resveratrol, 0.5 µM rapamycin or 60 µM resveratrol plus 0,5 µM rapamycin. The diagrams show the 
mean values of experiment 2 and 3 combined, with the dark gray scale showing 48 hours after 
treatment and the light gray as 72 hours. The ranges of the observations are showed with error bars. No 
statistic analyses were made due to the small number of observations. The untreated cells are had 
mean values of 630, 414, 241 and 100 for the peak, nucleus, cytosol and lamellipodia, respectively. 
 
  
  
  
4.3 AFM images 
In Figure 19 the two pictures are of the same resveratrol-treated cell (48 hours, 
experiment 3), comparing the phase contrast image and the AFM image. 
The three dimensional image shows the surface information as a two dimensional 
image. The bright sports in the two dimensional images (Figure 19B) appear as peaks in 
the three dimension images  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20). The control cell has less signs of nuclear collapse or no collapse at all. 
Resveratrol treated cell tend to collapse a lot and with the typical appearance of a 
fried egg. The information matches the data analysis.  
  
Figure 19 A) is obtained with a phase contrast microscope with a 20 times magnification before 
fixation. The peaks appear black in the phase contrast microscope and are thereby not a result of the 
fixation itself. B) The same cell was later identified and scanned in the AFM (atomic force microscope.) 
with numbers on; the peak of the nucleoli (1), nucleus  (2), cytosol (3) and lamellipodia (4).  Here the 
peaks of the nucleoli are illustrated as bright spots due to the light bar (not shown), which have been 
set so all 4 elements appear.  
 
 A)  phase contrast picture B)  AFM 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 three dimensional, grey scale pictures of cells obtained in AFM (atomic force microscopy). 
The height has been elevated for an illustrative effect, otherwise the cells would appear so flat that the 
details would be hard to distinguish, due to the height-area ratio (The cells are very flat and long). 
A) control B) resveratrol 
 
C)rapamycin D)Resveratrol +rapamycin 
  
 
4. Discussion 
As the samples obtained at 48 and 72 hours do not differ significantly, the discussion 
will combine these time points.  
The samples scanned in the AFM should not be used for quantity analysis, which can 
show statistic results but instead for high detailed pictures, with informative details. 
However some quantitative effects were used during the project to elevate the cell 
size difference in the different samples. This was also done by the help of phase 
contrast microscope, which is better suited for imaging many cells. By the help of the 
phase contrast we could observe the most abundant cell shape and then scan a cell 
with this morphology in the AFM. In for example the resveratrol treated samples, the 
cells have many different shapes but the most frequently cell shape was the fried 
egg-like cell, with a large area and very flat compared the untreated cells.  
Resveratrol also induced a different morphology, which looked astrocyte-like, with 
visible and long protrusions and a smaller area compared to the fried egg-like cells.  
The resveratrol treated cells have a bigger area, compared with the other groups. 
This observation is not new or differs from previously observations. We observed that 
the area of the resveratrol treated cells is about 8 times bigger than untreated cells. 
The rapamycin treated cells, have sizes corresponding to those of the controls, is 
interesting because as the rapamycin block both mTORC1 and mTORC2, we would 
aspect cell proliferation, cell size and actin organisation to be affected too. Therefore 
we state that resveratrol affects more then one substrate in the pathway to actin 
organisation and that the different isoforms of for example Akt are affected 
differently by rapamycin (mTORC1/2 inhibition) and resveratrol. Another explanation 
could be due to an elevated Akt activation in our cell culture, or that rapamycin 
enhance Akt activation when mTORC1 is blocked (and maybe also when mTORC2 is 
later blocked too). However other instruments/cells maybe give other results 
regarding rapamycin and cell size. Resveratrol seems to be involved in mTORC2 and 
the PI3K-Akt pathway, due to the effect on PKCα [Garcia-Garcia et al., 1999; Slater et 
al., 2003] and PI3K class II [Srivastava et al., 2005]. 
We only analyzed on cells after 48 and 72 hours, and according to Sarbassov et al. 
rapamycin inhibits mTORC2 after 24 hours [Sarbassov et al., 2006].  
 The cells treated with rapamycin plus resveratrol have an area size larger than the 
rapamycin-treated, but smaller than the resveratrol treated. It seems that both drugs 
decreases the effects of the other, but not inhibits or adds an additive effect of the 
drugs combined.  
Maybe the area increase is a result of the cell structure collapsing; the large-area 
resveratrol-treated cells, showed to be very flat compared to the control. The 
rapamycin-treated cells seem to be flat too. The structures of the nucleus and cytosol 
are affected most regarding height decrease- This could be a result of the cell 
collapse due to the fixation and hydration procedure or due decreased protein 
concentration. The AFM stresses the cell when the tip taps the sample but we would 
anticipate the same sheer stress to all the cells and that the stress is minimal due to 
mode we scan in. However the rigid structures of the membrane could maybe 
increase this friction. We have based our assumptions on the thesis that the fixation 
does not affect the cells differently. The target of rapamycin is intracellular, but 
resveratrol targets membrane bound substrates such as PI3K and PKCα (and 
probably others). We don not how the effects of the fixation technique influence this. 
This also applies for the active membrane bound Akt.  
The cells with visible upright protrusions (also described as peaks of nucleoli) seem 
only to appear in the cells treated with resveratrol (also in a combination with 
rapamycin), but as resveratrol tend to flatten the cell, it is not yet possible to say if the 
peaks is visible because the rest of the cell is collapsed or if resveratrol makes the cell 
produce them. The peak of the different treated cells have almost the same heights 
and the could therefore also be present in the untreated and rapamycin-treated 
cells, although not visible in the phase contrast images. We can observe that 
resveratrol changes the morphology of the horizontal protrusions, which are made of 
actin. It could be tempting to view the upright protrusions as actin-containing 
microvillus-like structures due to similarities with epithelial colon cells in vivo and the 
effect resveratrol on colon cancer. However the protrusions have previously been 
described as peak of nucleoli, our colon cancer cells have been cultured in vitro and 
we will therefore not state otherwise. 
 
 6. Conclusion and Perspective 
In the beginning of this project, we suspected resveratrol to be involved in mTOR and 
by using a well known mTOR inhibitor, we hoped to prove this. We did not know, at 
that time, that mTORC2 was sensitive to rapamycin, but based on the different cell 
sizes and height, we can conclude that resveratrol is indeed involved in the mTOR 
pathway. Resveratrol still changes the cell morphology (although to a lesser degree), 
when mTORC2 is inhibited by rapamycin, and some of the effects of resveratrol are 
thereby not mTORC2-dependent. This statement is based on that we did actually 
block mTORC2 completely.  
Because we treated our cells with rapamycin for more than 24 hours, Rictor was 
inhibited as well. The mTORC2 complex act as PDK2 and phosphorylates Akt, which is 
involved in cell morphology. We thereby diminished the effect of resveratrol by 
treating with the combination. The isoforms of mTORC2 and mSIN1 might not all be 
affected and this could be the reason for an effect of the combination, somehow 
between the two sole treatments. This could also be true for Akt isoforms and proteins 
such as Cdc42 and PKCα, which are involved in F-actin assembly. 
We suggest that if a similar experiment was done if could benefit if samples of, say 12 
and 24 hours also were included. Hereby the effects of rapamycin, before it inhibited 
mTORC2 assembly, could be monitored. If the samples also were marked with 
fluorescence, the actin-filaments could be identified. We also suggest an 
immunoblotting of the proteins involved in the two mTOR complexes, and the isoforms 
of mTORC2, Akt, mSIN1 plus the classes and isoforms of PI3K. It could also be 
interesting to change the amount of nutrients to the cells, to see if the morphology of 
cells exposed to caloric restriction would mimic the effects of resveratrol when 
scanned in the AFM. When using cancer cells, the energy pathways could also be 
investigated as rapid growing cancer cells tend to rely on glycolysis.  
We chose to focus on the cytoskeleton, but other parts of the cell could also be 
interesting to investigate. Other cell lines could be interesting to study too, due to the 
knowledge of cancer cells with blocked, mutated and up- or down-regulated 
expressions of different proteins and pathway. The same could be done to more 
primitive organism such as yeast, roundworms or slime moulds with well-described 
and less complex pathways. 
 The AFM provides new possibilities for the areas of biological, medical and chemical 
research. Its major advantage is the detailed three dimensional pictures. It is time 
consuming and a certain technical knowledge is necessary to work with the AFM. We 
had to use a lot of Ph.D. Stud P.K. Kristoffersens time as we were not sufficient skilled in 
this device ourselves. A bigger study group or more time is therefore required if the 
AFM combined with other techniques are used. Fewer scanned cells could maybe 
help to overcome this problem. Scanning living cells in liquid would remove the 
uncertainties regarding the fixation and dehydration before scanning cells in air. We 
look forward to see the progress of this evolve at our institute. 
Because of the now proteins involved in the pathways described in this project, a 
more detailed image should be presented. We hope to be able to present this for the 
evaluation. As mTOR and Akt is still evolving, there would maybe be a new conclusion 
when new knowledge as added.   
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